What is not clear, but is concerning, is that with the diminished use and availability of culture for diagnostic purposes, fewer tests are being performed to detect gonorrhea at rectal and pharyngeal sites.

The percentage of tests for gonorrhea that are performed with NAATs has been increasing over time, reflected by a recent CDC survey indicating that only 5% of all gonorrhea tests performed in public health laboratories were by culture. Unlike culture, NAATs are currently not FDA approved for use in the rectum, pharynx, and conjunctiva however, some public and large private laboratories have conducted validation tests to meet Clinical Laboratory Improvement Amendment requirements, allowing them to perform these tests at pharyngeal and rectal sites. Nucleic acid amplification tests (NAATs) permit testing of the widest range of specimen types and are Food and Drug Administration (FDA)-approved for use with endocervical, vaginal, and male urethral swabs and urine specimens from females and males. gonorrhoeae requires testing at specific anatomic sites of infection. gonorrhoeae infections of the pharynx are more difficult to eradicate than infections at urogenital and anorectal sites, and ceftriaxone is the only recommended regimen for treating pharyngeal infections.Дiagnosis of N.

Oral cephalosporins have insufficient efficacy for treating gonococcal infections of the pharynx and should not be used in persons in whom pharyngeal infection is suspected. gonorrhoeae for urogenital and anorectal infection, but none have substantial advantages over the recommended regimens. Several other alternative oral cephalosporins are active against N. Cefixime (400 mg) is the only oral regimen recommended for urogenital and anorectal gonorrhea treatment. Ceftriaxone, available only as an injection, is the recommended regimen for uncomplicated urogenital, anorectal, and pharyngeal infection. gonorrhoeae (QRNG) in the United States, there is only a single class of antimicrobials among the recommended gonorrhea treatment options: the cephalosporins. Д«ecause of the recent emergence of quinolone-resistant N. However, gonorrhea treatment has been complicated by the development of resistance to multiple classes of antimicrobials over the past 60 years. Effective treatment not only eradicates infection in the affected individual and prevents the development of complications, it also has an important public health benefit by shortening the duration of infection, thus decreasing transmission and eliminating reservoirs of infection. An essential element in gonorrhea control is the availability and provision of effective antimicrobial therapy. Neisseria gonorrhoeae can cause cervicitis, urethritis, proctitis, pelvic inflammatory disease with long-term sequelae (eg, infertility, ectopic pregnancy, and chronic pelvic pain), adverse outcomes of pregnancy, and increased susceptibility to and facilitated transmission of human immunodeficiency virus (HIV) infection. The actual number of infections per year is thought to be much higher because of underdetection and underreporting.

In 2008, >330,000 cases of gonorrhea were reported to the Centers for Disease Control and Prevention (CDC).

Pharyngeal gonorrhea symptoms